Calluna Pharma has concluded the Phase I clinical study of its lead product, CAL101, for fibrotic and fibro-inflammatory indications. CAL101 is a first-in-class monoclonal antibody (mAb) targeting the ...

NAARDEN, The Netherlands & OSLO, Norway--(BUSINESS WIRE)--Oxitope Pharma (Oxitope) and Arxx Therapeutics (Arxx), companies with a shared goal of leveraging the innate immune system to discover and ...

OSLO, Norway--(BUSINESS WIRE)--Calluna Pharma AS (Calluna), a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory and fibrotic diseases, today announced the ...

Executive appointments will drive growth strategy and progression of clinical pipeline OSLO, Norway & BOSTON, October 09, 2024--(BUSINESS WIRE)--Calluna Pharma AS (Calluna), a clinical stage ...

Oxitope Pharma and Arxx Therapeutics have announced their merger to form Calluna Pharma, which has raised €75m in a series A financing, to develop novel therapies for immunological diseases. The new ...

The MarketWatch News Department was not involved in the creation of this content. Study of CAL101, which targets a novel upstream pathway implicated in fibrotic disease, enrolls 161 patients more than ...

Calluna Pharma AS has announced the successful completion of Phase 1 clinical trials for its lead drug candidate, CAL101, a first-in-class monoclonal antibody (mAb) targeting fibrotic and ...

Calluna Pharma Inc., formed last year following the merger of Oxitope Pharma BV and Arxx Therapeutics AS, has raised €75 million (US$81.4 million) in a series A financing.

Study of CAL101, which targets a novel upstream pathway implicated in fibrotic disease, enrolls 161 patients more than six months ahead of plan; topline data expected Q1 2027 Drug candidate, a ...

Calluna Pharma AS (Calluna), a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory and fibrotic diseases, today announced the appointments of Mark Gaffney ...